<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2921">
  <stage>Registered</stage>
  <submitdate>16/09/2010</submitdate>
  <approvaldate>16/09/2010</approvaldate>
  <nctid>NCT01204762</nctid>
  <trial_identification>
    <studytitle>Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen</studytitle>
    <scientifictitle>Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients With Chronic Hepatitis B Virus Infection Who Are HBeAg-positive</scientifictitle>
    <utrn />
    <trialacronym>LIRA-B</trialacronym>
    <secondaryid>2010-020387-38</secondaryid>
    <secondaryid>AI452-005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B Virus</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - pegIFN
Treatment: drugs - pegIFNa-2a
Treatment: drugs - PegIFN lambda
Treatment: drugs - Entecavir

Experimental: Part A Arm 1: pegIFN (180 µg) - 

Active Comparator: Part A Arm 2: pegIFNa-2a - 

Experimental: Part B: pegIFN lambda + Entecavir - 


Treatment: drugs: pegIFN
Syringe, Subcutaneous, 180 µg, Once Weekly, 48 weeks

Treatment: drugs: pegIFNa-2a
Syringe, Subcutaneous 180 µg, Once Weekly, 48 Weeks

Treatment: drugs: PegIFN lambda
Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks

Treatment: drugs: Entecavir
Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Part A: Proportion of subjects who achieve Hepatitis B e antigen (HBeAg) seroconversion</outcome>
      <timepoint>24 weeks post-dosing (Week 72)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part A: Number and percent of subjects with serious adverse events (SAEs) and discontinuations due to adverse events</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part A: Number and percent of subjects with serious adverse events (SAEs) and discontinuations due to adverse events</outcome>
      <timepoint>24 weeks post-dosing (Week 72)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part B: Safety and tolerability of Lambda/ETV regimen as measured by the frequency of SAEs and discontinuations due to AEs</outcome>
      <timepoint>Up to 84 Weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Proportion of subjects who achieve an hepatitis B virus Deoxyribonucleic acid levels (HBV DNA) &lt; 50 IU/mL (approximately 300 copies/mL) using the Roche COBAS® TaqMan - High Pure System (HPS) assay</outcome>
      <timepoint>Weeks 24, 48, 72, 96, 120, 144, 168 and 192</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Mean change from baseline in log10 HBV DNA levels over time (Proportion of subjects with Alanine amino transferase (ALT) normalization (= 1 x upper limit of normal (ULN))</outcome>
      <timepoint>Baseline (Day 1), Weeks 24, 48, 72, 96, 120, 144, 168 and 192</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Proportion of subjects with ALT normalization (= 1 x ULN)</outcome>
      <timepoint>Weeks 24, 48, 72, 96, 120, 144, 168 and 192</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Hepatitis E antigen (HBeAg) loss</outcome>
      <timepoint>Weeks 24, 48, 72, 96, 120, 144, 168 and 192</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: HBeAg seroconversion</outcome>
      <timepoint>Weeks 24, 48, 96, 120, 144, 168 and 192</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Mean change from baseline in log10 quantitative HBeAg levels over time</outcome>
      <timepoint>Baseline (Day 1), Weeks 24, 48, 96, 120, 144, 168 and 192</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Number and percent of subjects with adverse events (AEs) or laboratory abnormalities</outcome>
      <timepoint>Up to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Number and percent of subjects with adverse events (AEs) or laboratory abnormalities</outcome>
      <timepoint>Up to Week 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Pharmacokinetic (PK) parameter Maximum observed concentration (Cmax) of Pegylated interferon lambda (pegIFN?) will be derived from serum concentration versus time data</outcome>
      <timepoint>Day 1 (including intense PK), Weeks 2, 4, 12 (including intense PK), 16, 24, 40, 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Pharmacokinetic (PK) parameter Time of maximum observed concentration (Tmax) of Pegylated interferon lambda (pegIFN?) will be derived from serum concentration versus time data</outcome>
      <timepoint>Day 1 (including intense PK), Weeks 2, 4, 12 (including intense PK), 16, 24, 40, 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: Pharmacokinetic (PK) parameter Trough serum concentration pre-dose (C0) of Pegylated interferon lambda (pegIFN?) will be derived from serum concentration versus time data</outcome>
      <timepoint>Day 1 (including intense PK), Weeks 2, 4, 12 (including intense PK), 16, 24, 40, 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: PK parameter serum concentration 168 hours post observed dose [Cmin] (C0 will be used as an estimate of Cmin if sample is not collected) of pegIFN? will be derived from serum concentration versus time data</outcome>
      <timepoint>Day 1 (including intense PK), Weeks 2, 4, 12 (including intense PK), 16, 24, 40, 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: PK parameter Area under the concentration-time curve in 1 dosing interval from time 0 to 168 hours post observed dose [AUC(TAU)] of pegIFN? will be derived from serum concentration versus time data</outcome>
      <timepoint>Day 1 (including intense PK), Weeks 2, 4, 12 (including intense PK), 16, 24, 40, 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part A: PK parameter Accumulation index (AI) ratio of AUC(TAU) at steady-state to AUC(TAU) after the first dose (only conducted if data warrant) of pegIFN? will be derived from serum concentration versus time data</outcome>
      <timepoint>Day 1 (including intense PK), Weeks 2, 4, 12 (including intense PK), 16, 24, 40, 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: HBeAg seroconversion rate at 24 weeks off treatment</outcome>
      <timepoint>Week 84</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Antiviral activity of Lambda/ETV regimen, as determined by the proportion of subjects who achieve an HBV DNA &lt; 50 IU/mL (approximately 300 copies/mL) using the Roche COBAS® TaqMan - HPS assay</outcome>
      <timepoint>Weeks 4, 8, 12, 24, 36, 60, and 84</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Mean change from baseline in HBV DNA over time in subjects treated with Lambda/ETV</outcome>
      <timepoint>Weeks 4, 8, 12, 24, 36, 60, and 84</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: HBeAg loss and seroconversion in subjects treated with Lambda/ETV regimen</outcome>
      <timepoint>Weeks 12, 24, 36, 60 and 84</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: HBeAg levels over time in subjects treated with Lambda/ETV regimen</outcome>
      <timepoint>Weeks 4, 8, 12, 24, 36, 60, and 84</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: biochemical response rates in subjects treated with Lambda/ETV regimen</outcome>
      <timepoint>Weeks 4, 8, 12, 24, 36, 60, and 84</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Pharmacokinetic (PK) parameter Maximum observed concentration (Cmax) of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome>
      <timepoint>Baseline (Day 1), Weeks 4, 12, 16, 24, 52, 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Pharmacokinetic (PK) parameter Time of maximum observed concentration (Tmax) of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome>
      <timepoint>Baseline (Day 1), Weeks 4, 12, 16, 24, 52, 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Pharmacokinetic (PK) parameter Trough serum concentration pre-dose (C0) of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome>
      <timepoint>Baseline (Day 1), Weeks 4, 12, 16, 24, 52, 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: PK parameter Area under the concentration-time curve in 1 dosing interval from time 0 to 168 hours post observed dose [AUC(TAU)] of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome>
      <timepoint>Baseline (Day 1), Weeks 4, 12, 16, 24, 52, 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: PK parameter serum concentration 168 hours post observed dose [Cmin] (C0 will be used as an estimate of Cmin if sample is not collected) of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome>
      <timepoint>Baseline (Day 1), Weeks 4, 12, 16, 24, 52, 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: PK parameter Accumulation index (AI) ratio of AUC(TAU) at steady-state to AUC(TAU) after the first dose (only conducted if data warrant) of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome>
      <timepoint>Baseline (Day 1), Weeks 4, 12, 16, 24, 52, 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Part B: Rate of resistance to ETV during treatment with the Lambda/ETV regimen</outcome>
      <timepoint>Up to Week 84</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Infection with the hepatitis B virus (HBV) and positive for the hepatitis B e antigen

          -  Between the ages of 18 and 70

          -  Have not been previously treated with an interferon

          -  HBV nucleos(t)ide-naive</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Not infected with the hepatitis C virus (HCV), hepatitis D virus (HDV) or human
             immunodeficiency virus (HIV)

          -  Do not have a serious liver, psychiatric, blood, thyroid, lung, heart or eye disease

          -  Able to tolerate oral medication</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>197</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,WA</recruitmentstate>
    <hospital>Local Institution - Camperdown</hospital>
    <hospital>Local Institution - Liverpool</hospital>
    <hospital>Local Institution - Westmead Nsw</hospital>
    <hospital>Local Institution - Clayton Vic</hospital>
    <hospital>Local Institution - Heidelberg Vic</hospital>
    <hospital>Local Institution - Melbourne</hospital>
    <hospital>Local Institution - Fremantle</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2170 - Liverpool</postcode>
    <postcode>2145 - Westmead Nsw</postcode>
    <postcode>3168 - Clayton Vic</postcode>
    <postcode>3084 - Heidelberg Vic</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6160 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clichy Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice Cedex 03</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 12</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tuebingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Tai Po</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Chuncheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-Do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>At least 1 dose of pegIFN? will be identified which is safe, well tolerated, and efficacious
      for the treatment of chronic hepatitis B virus infection (CHB)

      Amendment 7, Part B Sub Study: The primary purpose of this amendment is to obtain preliminary
      data on the safety of pegylated interferon Lambda (Lambda) when administered in combination
      with Entecavir(ETV) to patients with hepatitis E antigen-positive (HBeAg-positive) chronic
      hepatitis B(CHB) infection employing a sequential therapy approach</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01204762</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>